Phytotherapy for benign prostatic hyperplasia

Current Urology Reports

Volumn 3, Issue 4, 2002, Pages 285-291

  Gerber, Glenn S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Benign Prostatic Hyperplasia; Finasteride; Herbal Product; International Prostate Symptom Score; Lower Urinary Tract Symptom

Indexed keywords

ANTIANDROGEN; PLANT EXTRACT; SABAL EXTRACT; SITOSTEROL; SITOSTEROL DERIVATIVE;

CHEMISTRY; DRUG EFFECT; HUMAN; MALE; METABOLISM; PHYTOTHERAPY; POLLEN; PROSTATE; PROSTATE HYPERTROPHY; PRUNUS; REVIEW; SABAL; URODYNAMICS;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; POLLEN; PROSTATE; PROSTATIC HYPERPLASIA; PRUNUS; SERENOA; SITOSTEROLS; URODYNAMICS;

EID: 0036673059     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0050-3     Document Type: Article

References (42)

1. Lowe FC: Phytotherapy in the management of benign prostatic hyperplasia. Urology 2001, 58(Suppl 1):71–76. An excellent overview of the use of phytotherapy by men with BPH. DOI: 10.1016/S0090-4295(01)01303-6
2. Champault G, Patel JC, Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984, 18:461–462.
3. Cukier J, Ducassou J, Le Guillou M, et al.: Serenoa repens extract vs. placebo. Pharmacol Clin 1985, 4:15–21.
4. Emile E, LoCigno M, Petrone U: Clinical results on a new drug in the treatment of benign prostatic hyperplasia (Permixon). Urologia 1983, 50:1042–1049.
5. Smith HR, Memon A, Smart CJ, et al.: The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986, 58:36–40.
6. Delos S, Iehle C, Martin PM: Inhibition of the activity of basic 5-alpha reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994, 48:347–352. DOI: 10.1016/0960-0760(94)90074-4
7. Bayne CW, Grant ES, Chapman K, et al.: Characterisation of a new coculture model for BPH which expresses 5-alpha reductase types 1 and 2: the effects of Permixon on DHT formation [abstract]. J Urol 1997, 157(Suppl 4):755.
8. Sultan C, Terraza A, Devillier C, et al.: Inhibition of androgen metabolism and binding by liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 1984, 20:515–519. DOI: 10.1016/0022-4731(84)90264-4
9. Carilla E, Briley M, Fauran F, et al.: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984, 20:521–523. DOI: 10.1016/0022-4731(84)90265-6
10. Di Silverio F, Sciarra A, D’Eramo G, et al.: Response to tissue androgen and epidermal growth factor concentrations to the administration of finasteride, flutamide and Serenoa repens in patients with BPH [abstract]. Eur Urol 1996, 30(Suppl 2):80.
11. Rhodes L, Primka RL, Berman C, et al.: Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in vitro and in vivo 5-alpha reductase inhibition. Prostate 1993, 22:43–51. DOI: 10.1002/pros.2990220107
12. Strauch G, Perles P, Vergult G, et al.: Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994, 26:247–252.
13. Carraro JC, Raynaud JP, Koch G, et al.: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996, 29:231–240. DOI: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E
14. Gerber GS, Zagaja GP, Bales GT, et al.: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998, 51:1003–1007. DOI: 10.1016/S0090-4295(98)00143-5
15. Braeckman J: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994, 55:776–785. DOI: 10.1016/S0011-393X(05)80771-4
16. Di Silverio F, D’Eramo G, Lubrano C, et al.: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992, 21:309–314.
17. Helpap B, Oehler U, Weisser H, et al.: Morphology of benign prostatic hyperplasia after treatment with sabal extract IDS 89 or placebo. J Urol Pathol 1995, 3:175–182.
18. Marks LS, Partin AP, Epstein JI, et al.: Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000, 163:1451–1456. One of the first studies to convincingly demonstrate histologic changes in the prostate gland associated with saw palmetto use. This may begin to help explain the clinical effectiveness of saw palmetto in men with BPH. DOI: 10.1016/S0022-5347(05)67641-0
19. Descotes JL, Rambeaud JJ, Deschaseaux P, et al.: Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995, 9:291–297.
20. Plosker GL, Brogden RN: Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996, 9:379–395.
21. Smith HR, Memon A, Smart CJ, et al.: The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986, 58:36–40.
22. Gerber GS, Kuznetsov D, Johnson BC, et al.: Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001, 58:960–965. The results of this trial indicated significant improvement in urinary symptoms using saw palmetto compared with placebo. No significant change in peak urinary flow rate was noted. DOI: 10.1016/S0090-4295(01)01442-X
23. Wilt TJ, Ishani A, Stark G, et al.: Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review. JAMA 1998, 280:1604–1609. This meta-analysis of close to 3000 men concluded that saw palmetto was superior to placebo in relieving urinary symptoms in men with BPH. Although this study generated a great deal of coverage in the lay press, its findings are somewhat limited by the inclusion of many poorly conducted studies. DOI: 10.1001/jama.280.18.1604
24. Boyle P, Robertson C, Lowe F, et al.: Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000, 55:533–539. Significant improvement in urinary flow rates and symptoms were reported using a meta-analysis of 13 published trials of Permixon. DOI: 10.1016/S0090-4295(99)00593-2
25. Chopin DK, Perrin P, Authie D, et al.: Prostatic volume does not correlate with efficacy of treatment for mild to moderate benign prostatic hyperplasia using either finasteride or phytotherapy (Permixon). Paper presented at the 4th International Consultation on BPH. Paris, July 2–5, 1997.
26. Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996, 335:533–539. DOI: 10.1056/NEJM199608223350801
27. Yablonsky F, Nicolas V, Riffaud JP, et al.: Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 1997, 157:2381–2387. DOI: 10.1016/S0022-5347(01)64785-2
28. Paubert-Braquert M, Monboisse JC, Servent-Saez N, et al.: Inhibition of bFGF and EGF-induced proliferation of 3T3 fibroblasts by extract of Pygeum africanum (Tadenan). Biomed Pharmacother 1994, 48(Suppl 1):43–47.
29. Levin RM, Riffaud JP, Bellamy F, et al.: Effects of Tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 1996, 156:2084–2088. DOI: 10.1016/S0022-5347(01)65440-5
30. Krasnopolsky L, Zhao Y, Wein AJ: Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. J Urol 1996, 155:1466–1470. DOI: 10.1016/S0022-5347(01)66308-0
31. Choo MS, Bellamy F, Constantinou CE: Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone. Urology 2000, 55:292–298. DOI: 10.1016/S0090-4295(99)00407-0
32. Dufour B, Choquenet C, Revol M, et al.: Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma. Ann Urol 1984, 18:193–195. Small study of brief duration that suggested a significant improvement in urinary symptoms using Pygeum africanum compared with placebo.
33. Barlet A, Albrecht J, Aubert A, et al.: Wirksamkeit eines extraktes aus Pygeum africanum in der medikamentosen therapie von miktionsstorungen infolge einer benignen prostathyperplasi: betwertung objectiver und subjektiver parameter. Wien Klin Wochenschr 1990, 102:667–673.
34. Carbin BE, Larsson B, Lindahl O: Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1987, 66:639–641.
35. Berges RR, Windeier J, Trampisch HJ, et al.: Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995, 345:1529–1532. DOI: 10.1016/S0140-6736(95)91085-9
36. Berges RR, Kassen A, Senge T: Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18 month follow-up. Br J Urol 2000, 85:842–846. This open-label extension study using Harzol demonstrated persistently positive results using this form of beta-sitosterol after an 18-month follow-up.
37. Dreikorn K, Richter R, Schnohofer PS: Konservative, nicht-hormonelle Behandlung der benignen prostata-hyperplasia. Urologe A 1990, 29:8–16.
38. Klippel KF, Hiltl DM, Schipp B: Randomized, double blinded placebo controlled trial to evaluate the efficacy of B-sitosterol (phytosterol) in patients with obstructive and irritative symptoms due to BPH. Paper presented at the 4th International Consultation on BPH. Paris, July 2–5, 1997.
39. Buck AC, Cox R, Rees WM, et al.: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study. Br J Urol 1990, 66:398–404. DOI: 10.1111/j.1464-410X.1990.tb14962.x
40. Dutkiewicz S: Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 1996, 28:49–53. DOI: 10.1007/BF02550137
41. Ito R, Ishii M, Yamashita S: Cernitin pollen-extract (Cernilton): antiprostatic hyperptrophic action of Cernitin pollenextract (Cernilton). Pharmacometrics 1986, 31:1–11.
42. Rugendorff EW, Weidner W, Ebeling L, et al.: Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993, 71:433–438.